Atlas Trials

A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

Clinical trial NCT05133349 · UNKNOWN

Trial details

NCT number
NCT05133349
Sponsor
Nanjing First Hospital, Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced or Metastatic Paraganglioma/ Pheochromocytoma
Start date
2021-09-14
Primary completion
2023-09-14
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.